Abstract:Background: Cytoplasmic inclusions containing TAR DNA-binding protein 43 kDa (TDP-43) are recognized as a major pathological feature of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, but more recently have been associated with several neurodegenerative conditions. Cyclophilin A (PPIA), a foldase and molecular chaperone, interacts with TDP-43 and influences its aggregation and function. The interaction between PPIA and TDP-43 is facilitated by PPIA Lysacetylation, which is reduced in peripheral blood mononuclear cells (PBMCs) of ALS patients showing signs of TDP-43 proteinopathy. In this study, we investigated the effect of lysine deacetylation inhibition to uncover the underlying mechanisms of TDP-43 proteinopathy in relation to PPIA acetylation, and to identify new therapeutic avenues. Methods: Through a screening of histone deacetylase (HDAC) inhibitors in a cellular model of TDP-43 proteinopathy, we identified vorinostat/SAHA, capable of increasing PPIA acetylation, as the most effective in reversing TDP-43 mislocalization. We confirmed its effect in PBMCs from ALS patients. Next, we explored its impact on proteinopathy and PPIA acetylation in a severe and fast-progressing TDP-43 overexpressing mouse model (Thy1-hTDP-43), using several molecular biomarkers as outcome measures, including neurofilament light chain (NfL) in plasma. Results: Thy1-hTDP-43 mice treated with SAHA showed a delayed onset of TDP-43 pathology, associated with PPIA nucleus-cytoplasm redistribution, lower levels of neurodegeneration and neuroinflammation markers, and improved neuromuscular function markers. However, over time, the broad-spectrum inhibitor SAHA was unable to counteract the two-fold overexpression of TDP-43 and led to the accumulation of side effects. When combined with the heat shock protein (HSP) co-inducer arimoclomol, a mitigation of the neurodegeneration was sustained. Moreover, a synergistic effect was observed in periphery, greatly enhancing tubulin acetylation and reducing pTDP-43 accumulation in the sciatic nerve. This resulted in a more pronounced reduction of NfL in plasma and acetylcholine receptor (AChR) γ-subunit expression in gastrocnemius muscle, indicating reduced axonal transport impairment and muscle denervation. Conclusions: This study suggests that HDAC inhibition, by increasing acetylated PPIA, could be beneficial in restoring TDP-43 localization and function. The combination of lysine deacetylation inhibition and HSP induction shows a synergistic effect in vivo and has potential as a therapeutic approach for patients.

Stimulating VAPB-PTPIP51 ER-mitochondria tethering corrects FTD/ALS mutant TDP43 linked Ca2+ and synaptic defects

ER–mitochondria associations are regulated by the VAPB–PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43

Mitochondrial dysfunction heightens the integrated stress response to drive ALS pathogenesis

Targeting 14-3-3θ-mediated TDP-43 pathology in amyotrophic lateral sclerosis and frontotemporal dementia mice

Targeting Tau Mitigates Mitochondrial Fragmentation and Oxidative Stress in Amyotrophic Lateral Sclerosis

TDP-43 as a therapeutic target in neurodegenerative diseases: Focusing on motor neuron disease and frontotemporal dementia

TDP-43 Proteinopathy and Mitochondrial Abnormalities in Neurodegeneration

An ALS-associated Mutation Affecting TDP-43 Enhances Protein Aggregation, Fibril Formation and Neurotoxicity

TDP-43 Induces Mitochondrial Damage and Activates the Mitochondrial Unfolded Protein Response

Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration

Autophagic Modulation by Trehalose Reduces Accumulation of TDP-43 in a Cell Model of Amyotrophic Lateral Sclerosis Via TFEB Activation.

Lysine deacetylation inhibition reverses TDP-43 mislocalization and in combination with arimoclomol ameliorates neuromuscular pathology

α-Synuclein binds to the ER–mitochondria tethering protein VAPB to disrupt Ca2+ homeostasis and mitochondrial ATP production

TDP-43 regulates LC3ylation in neural tissue through ATG4B cryptic splicing inhibition

Glycolic acid and D-lactate--putative products of DJ-1--restore neurodegeneration in FUS - and SOD1-ALS

TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: From pathomechanisms to therapeutic strategies

ALS-Linked VapB P56S Mutation Alters Neuronal Mitochondrial Turnover at the Synapse

TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD

Activation of AMP-activated protein kinase α1 mediates mislocalization of TDP-43 in amyotrophic lateral sclerosis.

A TDP-43 acetylation-mimic mutation that disrupts RNA-binding drives FTLD-like neurodegeneration in a mouse model of sporadic TDP-43 proteinopathy

The Mtorc2/akt/vcp Axis is Associated with Quality Control of the Stalled Translation of Poly(gr) Dipeptide Repeats in C9-ALS/FTD